We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Claire McCaskill (D-Mo.) asked Mallinckrodt for more details on price increases for Ofirmev, the company’s injectable version of acetaminophen. Read More
A television advertisement for the Orexigen Therapeutics weight loss drug Contrave (naltrexone HCl and bupropion HCl) drew a warning from the FDA’s Office of Prescription Drug Promotion (OPDP), the office’s first of 2017. Read More
FDA Commissioner Scott Gottlieb pitches the agency’s proposed fiscal 2018 budget to House appropriators on Capitol Hill today, as industry and other stakeholders voice their concerns over the impact of the administration’s proposal. Read More